TABLE 3.
Inhibition of Plasmodium falciparum growth in infected human erythrocytesa
Test agents | IC50 (nM) |
||||||
---|---|---|---|---|---|---|---|
Particle size | Chloroquine-sensitive 3D7 |
Multidrug-resistant Dd2 |
|||||
Mean (μm) | Mean | SD | P value | Mean | SD | P value | |
Artemisinin | n/a | 7.900 | 2.260 | 15.910 | 3.730 | ||
Chloroquine | n/a | 32.060 | 11.030 | 364.500 | 45.080 | ||
DMSO dissolved DQ | n/d | 1.410 | 0.390 | 2.630 | 1.880 | ||
Nanoformulation DQ | 0.21 | 2.100 | 1.330 | 3.110 | 0.860 | ||
HME DQ (F15) | 0.47 | 2.390 | 1.230 | 3.530 | 0.740 | ||
Artemisinin verusus HME DQ | 0.021 | 0.005 | |||||
DMSO DQ versus Nano DQ | 0.437 | 0.708 | |||||
DMSO DQ VS HME DQ | 0.259 | 0.483 |
F15 DQ was more potent than artemisinin and chloroquine against two different P. falciparum strains in the in vitro test (P < 0.05). F15 DQ had inhibitory potency comparable to DMSO dissolved DQ and nano-DQ (P > 0.05). Each value represents triplicate and the experiment repeated multiple times; n/d, not detectable; n/a, not applicable.